Transarterial therapies for the treatment of intrahepatic cholangiocarcinoma

Seminars in Interventional Radiology

Volumn 30, Issue 1, 2013, Pages 21-27

  Zechlinski, Joseph J ^a   Rilling, William S ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

chemoembolization; cholangiocarcinoma; outcomes; radioembolization

Indexed keywords

EID: 84874392025     PISSN: 07399529     EISSN: 10988963     Source Type: Journal    
DOI: 10.1055/s-0033-1333650     Document Type: Article

References (34)

1. Khan S. A., Thomas H. C., Davidson B. R., Taylor-Robinson S. D. Cholangiocarcinoma. Lancet: 2005; 366 9493 1303 1314
2. Farley D. R., Weaver A. L., Nagorney D. M. "Natural historyo" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc: 1995; 70 5 425 429
3. Shaib Y., El-Serag H. B. The epidemiology of cholangiocarcinoma. Semin Liver Dis: 2004; 24 2 115 125
4. Marsh RdeW, Alonzo M., Bajaj S., et al. Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part I: diagnosis-clinical staging and pathology. J Surg Oncol: 2012; 106 3 332 338
5. Yamamoto M., Ariizumi S. Surgical outcomes of intrahepatic cholangiocarcinoma. Surg Today: 2011; 41 7 896 902
6. Edge S. B. American Joint Committee on Cancer AJCC Cancer Staging Manual. 7th ed. New York; London Springer: 2010; 648
7. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg: 2003; 10 4 288 291
8. Nathan H., Aloia T. A., Vauthey J. N., et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol: 2009; 16 1 14 22
9. Valle J., Wasan H., Palmer D. H., et al. ABC-02 Trial Investigators Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med: 2010; 362 14 1273 1281
10. Harder J., Riecken B., Kummer O., et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer: 2006; 95 7 848 852
11. Ben-Josef E., Normolle D., Ensminger W. D., et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol: 2005; 23 34 8739 8747
12. Kopek N., Holt M. I., Hansen A. T., Hoyer M. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol: 2010; 94 1 47 52
13. Slakey D. P. Radiofrequency ablation of recurrent cholangiocarcinoma. Am Surg: 2002; 68 4 395 397
14. Carrafiello G., Laganà D., Cotta E., et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc Intervent Radiol: 2010; 33 4 835 839
15. Kim J. H., Won H. J., Shin Y. M., Kim K. A., Kim P. N. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol: 2011; 196 2 W205-9
16. Kim J. H., Won H. J., Shin Y. M., Kim P. N., Lee S. G., Hwang S. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol: 2011; 80 3 e221 e225
17. Fu Y., Yang W., Wu W., Yan K., Xing B. C., Chen M. H. Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol: 2012; 23 5 642 649
18. Llovet J. M., Real M. I., Montaña X., et al. Barcelona Liver Cancer Group Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet: 2002; 359 9319 1734 1739
19. Lo C. M., Ngan H., Tso W. K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology: 2002; 35 5 1164 1171
20. Burger I., Hong K., Schulick R., et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol: 2005; 16 3 353 361
21. Gusani N. J., Balaa F. K., Steel J. L., et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg: 2008; 12 1 129 137
22. Kim J. H., Yoon H. K., Sung K. B., et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer: 2008; 113 7 1614 1622
23. Kiefer M. V., Albert M., McNally M., et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer: 2011; 117 7 1498 1505
24. Vogl T. J., Naguib N. NN, Nour-Eldin N. E., et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. Int J Cancer: 2012; 131 3 733 740
25. Lewis A. L., Taylor R. R., Hall B., Gonzalez M. V., Willis S. L., Stratford P. W. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol: 2006; 17 8 1335 1343
26. Hong K., Khwaja A., Liapi E., Torbenson M. S., Georgiades C. S., Geschwind J. F. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res: 2006; 12 8 2563 2567
27. Varela M., Real M. I., Burrel M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol: 2007; 46 3 474 481
28. Aliberti C., Benea G., Tilli M., Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol: 2008; 31 5 883 888
29. Poggi G., Amatu A., Montagna B., et al. OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol: 2009; 32 6 1187 1192
30. Kuhlmann J. B., Euringer W., Spangenberg H. C., et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol: 2012; 24 4 437 443
31. Salem R., Thurston K. G. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol: 2006; 17 8 1251 1278
32. Ibrahim S. M., Mulcahy M. F., Lewandowski R. J., et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer: 2008; 113 8 2119 2128
33. Saxena A., Bester L., Chua T. C., Chu F. C., Morris D. L. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol: 2010; 17 2 484 491
34. Hoffmann R. T., Paprottka P. M., Schön A., et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol: 2012; 35 1 105 116